Skip to Content

Altimmune to Present at the 29th Annual Piper Jaffray Conference

Nov 21, 2017

GAITHERSBURG, Md., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, president and chief executive officer of Altimmune, will present a corporate overview at the 29th Annual Piper Jaffray Conference, taking place November 28-29, 2017 in New York, NY.

Presentation Details:  
Date: November 28, 2017
Time: 2:00pm Eastern Standard Time
Location: Lotte New York Palace Hotel; New York, NY

About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease and on the development of two next-generation anthrax vaccines that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines. The company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines.

Contacts:
Bill Enright                                          
President and CEO                         
Phone: 240-654-1450                     
Email: enright@altimmune.com

Ashley Robinson
Managing Director LifeSci Advisors
Phone: 617-535-7742
Email: arr@lifesciadvisors.com

 

 

Source: Altimmune, Inc.